



# Effectiveness

Failure rates expressed as failure rate per  
100 woman years(WY)



# How to choose?



- Cost
- STI protection
- Safety & side effects
- Comfort & ease of use
- Reversibility & fertility plan



**Most methods of contraception are safe for most women and the UK Medical Eligibility Criteria is a definitive reference guide concerning all methods of contraception, indicating which women can safely use which of the following methods:**

- Natural family planning
- Barrier methods
- Combined hormonal methods
- Progestogen-only oral contraception
- Injectable contraception
- Subdermal implants
- Intrauterine methods




# Definition of UKMEC category

UKMEC	Definition of category
1	A condition for which there is <b>no restriction</b> for the use of the contraception method
2	A condition where <b>advantages outweigh</b> theoretical or proven risks
3	A condition where the theoretical or proven <b>risks usually outweigh</b> the advantages of using the method.
4	A condition which represents an <b>unacceptable</b> health risk if the contraceptive method is used.



# Natural family planning NFP

- Cycle or rhythm method(calendar method)
- Temperature method
- Cervical mucus method(Billing's method)
- Lactational amenorrhea method(LAM)



# Mode of action

Natural family planning methods involve a continual **awareness** of fertility including the day of ovulation.

## Effectiveness

The methods can be combined to increase effectiveness.



# Advantages of NFP

- May be the **only option** for couples with certain religious or cultural beliefs
- **Not medical**, with no need for visits to clinics
- Makes women **aware** of their ovulation cycle and natural fertility
- Can enhance **communication** and cooperation within a relationship.





# Disadvantages of NFP

- Higher failure rates
- Rely on the fact that conception days are known
- Long periods of abstinence
- No protection against STIs



# LAM

- Exact mechanism poorly understood
- ?? Inhibition of normal pulsatile LH - anovulation
- > 98% effective if **Fully**, < 6/12, **Amenorrhoeic**
- No medical conditions where LAM is restricted
- **Alternative contraception when:**
  - Reducing the **frequency** of breast-feeding
  - Stopping **night** feed /baby sleeps through the night
  - **Separation** from the baby (e.g. returning to work)
  - Introducing **supplements** (e.g. drinks or even small amounts of solids)
  - **Anxiety**, stress or illness in either the mother or the infant.



# Barrier methods

- **Male condoms**

Latex rubber, polyurethane

- **Female condoms(Femidom)**

FR 5-21/100WY

- **STI/HIV prevention**

- **Diaphragm/cervical cap/sponge and spermicides**

- ❖ Effectiveness

Depends on the **quality and consistency of use**. Failure rates range from four to 20 per 100 woman-years.



# Mode of action

Prevent fertilisation by **preventing sperm reaching** the female upper genital tract.

## Indications

- Client choice
- Medical reasons to exclude hormonal methods
- Intermittent or infrequent intercourse
- while a new method is taking effect
- can also be used with another method for protection against sexually transmitted infection.



## Advantages

- Male condoms are **widely available** without requiring a visit to a health professional
- Male and female condoms offer **protection against sexually transmitted infections** – diaphragms and caps do not
- **No** systemic side effects
- **No** effect on lactation
- Spermicides provide **lubrication**
- **Decreased risk** of malignant and premalignant cervical disease.



## Disadvantages

- high rates of **failure** with 'typical use'
- **Not acceptable** in some relationships
- Diaphragms need **fitting at a clinic** and the woman needs to learn to fit them herself
- The **size** of diaphragm needs to be changed when there is a weight change of  $\pm 4$  kg





# Combined hormonal contraception CHC

- Pills – monophasic & bi-/tri-phasic
- Patches
- Vaginal ring



# Mode of action

- Inhibit **ovulation**
- Alteration of **vaginal and cervical mucus** & inhibition sperm transport
- Atrophic **endometrium**-non-receptive



## Advantages

- Reliable
- Reversible
- Independent of IC
- Non-contraceptive benefits

## Disadvantages

- **Minor side effects**, e.g. nausea, fluid retention, weight gain
- **Increased** risk of **VTE**, secondary to the estrogen-induced effect on clotting factors
- **Increased** risk of **arterial disease**
- **Interactions** with some drugs causes reduction of efficacy
- Missed pills, vomiting and diarrhoea can cause loss of **efficacy**





# COCP

## Effectiveness

0.2–8 / 100 WY, depending on reliability of use

- Monophasic (Fixed dose)  
20-35 $\mu$ g EE+ progestogen
- Variable dose(phasic)
- Administered on a 21:7 day basis  
(continuous pill-taking regimens)
- 1<sup>st</sup> 7 tablets inhibit ovulation
- 14 to maintain anovulation



# Constituents of COCPs

- **Oestrogen**

Ethinylestradiol

20-35µg

Estradiol valerate

Estradiol

- **Progestogen**

Norethisterone(NET)

Norethindrone(NE)

Levonorgestrel(LNG)

Norgestrel(NG)

Desogestrel(DSG)

Gestodene(GSD)

Norgestimate(NGM)

Drospirenone

Cyproterone acetate

Dienogest

Nomegestrol acetate



# Non-contraceptive benefits

## Decrease

- **Menstrual disorders**
  - menorrhagia, irregular bleeding: 50%
  - dysmenorrhea: 40%
  - PMS
- **Functional ovarian cysts**
- **Benign ovarian tumours**
- **Benign breast disease**
- **PID**
- **50% endometrial and ovarian cancer**-15 yrs after stopping
- **colorectal cancer: 20%**
- **Protective against RA, thyroid disease and duodenal ulcer**



# Major side effects

- **Venous thrombo-embolism(VTE)**

highest 1<sup>st</sup> year

non-user 5/100.000 WY

2<sup>nd</sup> generation(LNG) 15/100.000

3<sup>rd</sup> generation 25/100.000

pregnancy 60/100.000

- **MI and stroke**

increases with smoking, HTN

- **Migraine**

risk of ischemic stroke increases  
with aura UKMEC 4

- **Cancer**

Breast small increase 10/1000 non-pill users to 11/1000 pill users  
10 yrs after D/C to background risk

Cervical slight increased risk

Liver slight increase in benign and malignant tumours



# Side effects

## Oestrogenic

- Breast tenderness
- bloating
- weight gain
- nausea
- non-infective vaginal discharge
- some headaches
- Chloasma
- Photosensitivity

## Progestogenic

- Acne
- Greasy skin/hair
- hirsutism
- depression
- loss of libido
- vaginal dryness



# Contraindications

The UK Medical Eligibility Criteria for  
Contraceptive Use (UKMEC) 2016

<https://www.fsrh.org/documents/ukmec-2016/>



## Absolute C/I to COC

- Past or present CVD
- Hx of VTE or current VTE on anticoagulants
- Thrombogenic mutations
- Familial hypercholesterolaemia
- IDDM with complications (e.g. retinopathy)
- BP consistently >160/95
- Smokers >35 years, >15 cig/day
- BMI  $\geq 40$
- Focal migraine with aura
- Stroke
- Major surgery with prolonged immobilisation

## Relative C/I to COCP

- Family history (first-degree relative) of VTE aged under 45 years
- Systolic BP: 140–159 mmHg; diastolic BP: 90–94  
BMI 30–35
- Focal migraine with aura >5 years ago



## Absolute C/I

- Active **liver** disease  
Porphyria
- 
- **Medical condition**  
affected by sex steroids  
e.g. chorea
- Undiagnosed genital tract  
**bleeding**
- **Estrogen-dependent**  
**tumours** e.g. breast  
cancer

## Relative C/I

- Some **malabsorption**  
conditions
- Conditions requiring **drug**  
**that which may interact**  
with COCP (some  
antiretrovirals, some  
anticonvulsants, some  
antitubercular agents)
- Medically treated and  
current **gall bladder**  
disease





# Initial assessment for CHC

- Past contraceptive use, obstetric hx, menstrual
- General health status:
  - drug use
  - medical as migraine, epilepsy
  - risk factors for VTE
  - sexual Hx
  - family Hx
  - smoking
- BP
- BMI



# When to start CHC?

- Menstrual cycle
- Amenorrhoeic
- Postpartum
- Miscarriage




**I forgot  
to take  
my** 



# Missed pills


**one pill**



**Continuing contraceptive effect**

**Take the missed pill when remembered**

**The remaining pills as usual**



**EC is NOT usually required**



# If 2 or more pills



## Continuing contraceptive effect

Take the most recent pill ASAP

The remaining pills as usual

Condoms or abstinence for 7 days



Pills 1-7: EC is required if UPSI in the PFI or 1<sup>st</sup> week

Pills 8-14 : No EC if preceding 7 pills were taken

Pills 15-21 : Omit the PFI by finishing the pills in the current pack and starting a new pack the next day



# Follow up

- 3 months after 1<sup>st</sup> prescription
  - BP
  - Any changes in risk factors
  - Further instruction
  - Assessment of any problems



# Breakthrough bleeding BTB

- Default ( 2-3 days after missed pill)
- duration of use( 1<sup>st</sup> few months)
- Disease(Chlamydia, cervical)
- Pregnancy
- Drugs
- D&V
- Disturbance of absorption
- Dose(low dose pills)



# Progestogen-only Contraception

## Types

- Progestogen-only pill (POP)
- Injectables
- Implants
- Intrauterine systems (IUS)





# Progesterone-only pills(POPs)

## Mode of action

- Alter **cervical mucus** & prevent sperm penetration
- Non receptive endometrium/ tubal motility
- May inhibit ovulation up to 60%  
Desogestrel-only pill-Cerazette-97%

## Effectiveness

- FR 0.3-0.8/100WY
- Age > 40yrs, lower FR
- Weight - no evidence of reduced efficacy with increased weight



# POPs

- 3-hour window period
- Cirazette 12 hours



# Progesterone-only Injectable contraception POIC

- Depot medroxy progesterone acetate(DMPA) 12-weekly
- Norethisterone enanthate(NET-EN) 8-WEEKLY

## Mode of action

- Inhibit ovulation
- Thickening of Cx mucus prevents sperm penetration
- Changes in endometrium



# POIC

- FR per 100 women-years DMPA  
0.3 (ideal use)
- Delayed return of fertility up to 18 months
- linked to weight gain
- DMPA is associated with a small reversible reduction in bone mineral density as a result of hypoestrogenism with long-term treatment



# Progestogen-Only Implant POI

## Implanon

- Single rod/68 mg etonogestrel(ENG)/ 3 yrs

## Mode of action

- Inhibition of ovulation
- Thickening of Cx mucus
- Endometrial changes

## Side effects

Bleeding problems & weight gain

Complications with removal



# Indications

- Women with unacceptable side effects from estrogen or contraindications to its use e.g. smokers over the age of 35, migraine with aura
- DMPA can be used while awaiting sterilisation or a vasectomy to be effective
- Safe during lactation
- DMPA and IUS have high rates of amenorrhoea and are regularly used in the management of heavy menstrual bleeding, dysmenorrhoea and endometriosis.



# Contraindications

- Sensitivity or side effects to progestogens
- Pregnancy
- Undiagnosed vaginal bleeding
- Breast cancer

<https://www.fsrh.org/documents/ukmec-2016/>





# Disadvantages

- Irregular bleeding and changes in the bleeding pattern are the major side-effects of these methods
- Implants and IUS need to be inserted and removed by a healthcare practitioner, with the associated procedural risks.



# Long-Acting reversible contraception(LARC)

- Non-hormonal: IUCD or Cu-IUD
- Hormonal: (LNG-IUS, POIC, POI)



# IUCD and LNG-IUS


Standard T-shaped IUCD 380mm<sup>2</sup> copper

10yrs

Other Cu-IUDs and LNG-IUS for 5yrs

FR < 2%

0.2-2 HWY




# IUCD&IUS

## Mode of action

- Inhibit fertilization by **direct toxicity**
- Anti-implantation **inflammatory reaction** within endometrium
- **Copper in Cx mucus** inhibits sperm penetration
- **LNG-IUS** mainly on endometrium and Cx mucus



# Mirena-IUS



# Insertion & removal

- STI risk assessment (sexual Hx)
- Screening
- Prophylactic Abx
- Timing
- Follow up



# IUCD-IUS Risks



- **Expulsion**  
1/20 in the first 3/12, menstruation
- **PID**  
6-fold increase 1<sup>st</sup> 3 weeks  
overall risk is low unless STI exposure
- **Perforation** 2/1000, MC at insertion
- **Ectopic pregnancy** 0.02/100WY (0.3-0.5/100WY non-users)
- **bleeding pattern & pain**
- **Vasovagal syncope**
- **Lost threads**
- **Pregnancy**



# D.Dx of missed thread

- Expulsion
- Perforation
- Pregnancy
- Short thread

Mx U/S, abdominal X-ray



# Pregnancy with IUCD

- R/O ectopic
- Remove <12 wks if visible thread
- Increased risk of 2<sup>nd</sup> trimester miscarriage, PTD& infection if left in situ
- Small risk of miscarriage with removal





# Hormonal side effects(IUS)

- Bleeding pattern/ blackish discharge
- Headache
- Mood changes
- Acne
- Breast tenderness
- Change in libido
- Ovarian cysts-functional



# IUCD – UKMEC 4

- Pregnancy, puerperal sepsis and immediate post-septic abortion
- **Unexplained vaginal bleeding** – initiation of the method
- **GTD** – persistently elevated beta HCG levels or malignant disease
- **Cervical cancer** – initiation of the method in women awaiting treatment
- **Endometrial cancer** – initiation of the method
- **Ovarian cancer** – initiation of the method
- **Current PID**, symptomatic and asymptomatic chlamydial infection or purulent cervicitis or gonorrhoea – initiation of the method
- **Pelvic tuberculosis** – initiation of the method



# LNG-IUS – UKMEC Category 4

- Puerperal **sepsis**
- **Post-septic abortion**
- Unexplained vaginal **bleeding** – initiation of the method
- **GTD** – persistently elevated beta HCG levels or malignant disease
- **Cervical cancer** – initiation of the method in women awaiting treatment
- **Endometrial cancer** – initiation of the method
- **Ovarian cancer** – initiation of the method
- **Breast cancer – current**
- **Current PID**, symptomatic and asymptomatic chlamydial infection or purulent cervicitis or gonorrhoea – initiation of the method
- **Pelvic tuberculosis** – initiation of the method

It's always a good idea  
to have a back up plan.



# Emergency contraception

- **Hormonal method**

Progestogen-only EC

**Levonorgestrel-Levonelle 1500**

ASAP after UPSI- 72hrs

(73-120 hrs limited evidence of efficacy)

more than once in a cycle

double dose if using liver enzyme-inducing drugs

## Mode of action

- Alters Cx mucus & impairs sperm transport
- Inhibit ovulation



# Ulipristal acetate-ellaOne

- One 30mg tablet
- Selective progesterone receptor modulator
- 72-120 hrs of UPSI
- Effective as Levonelle
- Repeat dose not advised in the same cycle




# EC

- **IUCD**

- Cu-IUCD inserted up to 5 days of first episode of UPSI and up to 5 days of the estimated day of ovulation
- Effective immediately
- Long-term
- FR 1%
- screening for STIs/prophylactic Abx
- C/I same as IUCD



If **1000** women have a single act of unprotected sexual intercourse (UPSI) within a cycle:



Approximately **80** women would be pregnant if **none** of them used any EC.



Approximately **10** women would be pregnant if they all used **POEC**.



Approximately **1** woman would be pregnant if they all used **EC IUD**.





# Side effects and risks

- Vomiting
- Timing of the next menses
- Ectopic pregnancy
- No evidence teratogenicity



# Sterilization

- ❖ Permanent / Usually irreversible
- ❖ Counselling includes options, risks, benefits and failure rates


## Female –tubal occlusion


FR 1/200

## Male sterilization- vasectomy

FR 1/2000

Early and late failure





# Contraception after 40

- Natural decline in fertility mid-30s
- No contraceptive method is C/I by age alone.



# History(all types of contraception)

## Age

- Current contraception
- Past contraception
- Pregnancy
- Past major illness and operations
- Allergies
- Regular medication (including herbal remedies)
- Menstrual history
- Previous gynaecological history
- STIs and sexual history
- Smoking
- Cervical smear history
- Family history



Thank you!

